Nelson Advisors: The Fast Moving Consumer Healthcare Paradigm - Adapting FMCG Media Strategies to Regulated Everyday Health
The consumer healthcare industry is experiencing an operational and commercial transformation. Over the counter (OTC) medicines, oral care, and nutritional wellness brands, historically managed as downstream commercial offshoots of research-and-development-driven pharmaceutical conglomerates, are decoupling from corporate biopharmaceutical parents. Operating as independent, market responsive commercial entities, these businesses face fundamentally restructured corporate mandates.
This corporate unbundling coincides with profound structural shifts in consumer health literacy, proactive self-care behaviour and the retail media revolution. Consumer healthcare enterprises are increasingly adopting the media planning, brand-building and commercialisation strategies of Fast Moving Consumer Goods (FMCG) and Consumer Packaged Goods (CPG) companies.
Transitioning from traditional pharmaceutical marketing models to high-velocity FMCG playbooks requires balancing empirical marketing science, such as Byron Sharp’s principles of mental and physical availability, with the non-negotiable compliance parameters of health regulatory authorities and data privacy statutes.
Structural Catalysts of the FMCG Convergence
The Pure Play Imperative: Pos -Demerger Operating Realities
Between 2022 and 2025, the global pharmaceutical architecture experienced a wave of structural separations as conglomerates divested their consumer health arms to focus capital allocation on high-margin, patent-protected biopharmaceuticals, specialty oncology, immunology, and mRNA vaccines. GlaxoSmithKline executed the demerger of Haleon in July 2022, creating a standalone enterprise stewarding brands such as Sensodyne, Advil, Panadol, and Voltaren.
Johnson & Johnson completed the spin-off of Kenvue in 2023, establishing an independent consumer health business managing household staples including Tylenol, Listerine, Neutrogena, and Calpol. Similarly, Sanofi finalised the sale of a 50.0% controlling stake in its consumer healthcare business, Opella, to American private equity firm Clayton, Dubilier & Rice (CD&R) in April 2025 for an enterprise valuation delivering approximately €10 billion in net cash proceeds.
Within an integrated pharmaceutical parent company, consumer health units were managed alongside clinical pipelines with decade long horizons, high regulatory risk, and centralised administrative structures. In contrast, divested consumer health businesses no longer rely on blockbuster drug discoveries. Instead, they must generate shareholder value through repeatable unit volume growth, pricing power, responsive supply chains and fast innovation cycles.
To deliver above-market organic growth in a global self-care market worth around £200 billion annually, these pure play entities are replacing slow, risk averse marketing regimens with the media efficiencies pioneered by Procter & Gamble, Reckitt, Unilever and Nestlé.
Standalone Consumer Health Entity | Divesting Parent Entity | Separation Year | Strategic Commercial Focus | Representative Power Brands |
Haleon | GlaxoSmithKline (GSK) | 2022 | Category leadership, science-led premiumization, and volume/mix growth | Sensodyne, Advil, Voltaren, Panadol, Centrum |
Kenvue | Johnson & Johnson | 2023 | Repeat-purchase packaged goods model, digital shelf optimization, and brand defense | Tylenol, Listerine, Neutrogena, Nicorette, Aveeno |
Opella | Sanofi (Partnered with CD&R) | 2025 | Agile private-equity backed operations, digital e-commerce expansion, and OTC challenger scale | Allegra, Doliprane, Dulcolax, Buscopan, Enterogermina |
The Consumerisation of Self Care and OTC Expansion
This corporate restructuring aligns with broader demographic and behavioural shifts. Global healthcare systems face mounting strain from aging populations, prompting government payers and national health services to encourage self-medication for minor conditions to reduce primary care bottlenecks. Economic analyses show that every dollar spent on over the counter medicines generates roughly seven dollars in savings for the United States public healthcare system, totaling over $100 billion in avoided public costs.
Concurrently, regulatory authorities have continued to approve prescription to OTC switches, transitioning clinically proven active ingredients directly into open-shelf retail. The OTC switch of Voltaren Arthritis Pain, for example, generated approximately 80% of total category revenue growth in topical pain relief upon market introduction.
As consumers bear greater out of pocket responsibility for everyday wellness, their product discovery and buying patterns increasingly match typical consumer packaged goods habits. With rising digital accessibility and eCommerce penetration, self-directed patients evaluate analgesics, allergy therapies, digestive aids and upper respiratory treatments using standard FMCG criteria: brand familiarity, online customer reviews, immediate availability and price-pack architecture.
The global OTC market reached $58.2 billion in 2025, driven by an expanding consumer demographic that expects immediate omni channel access over traditional physician consultations.
Adapting FMCG Strategic Media and Brand Frameworks
The Transition to Mental and Physical Availability
Consumer healthcare marketing historically relied on a split, deterministic model: deploying sales forces to detail products directly to healthcare professionals (HCPs) to secure physician recommendations, while running seasonal linear television campaigns focused on clinical demonstrations and functional claims.
While healthcare professional recommendations remain a powerful commercial lever, driving an 87% increase in units purchased and an 86% increase in retail store trips, the primary driver of purchase volume in open-shelf and digital retail is brand salience.
Consumer healthcare marketing teams are adopting the empirical marketing principles developed by the Ehrenberg-Bass Institute. Under this framework, brand growth depends on expanding household penetration rather than cultivating narrow attitudinal brand loyalty. This requires coordinating two strategic levers:
1) Mental availability represents the likelihood that a consumer will notice, recall, and consider a brand within a specific purchase situation. Rather than relying on generic condition awareness, modern consumer health media plans are organised around Category Entry Points (CEPs), the situational and emotional contexts through which category buyers enter the market. For an analgesic, CEPs extend beyond severe physical pain to daily triggers such as post-exercise muscle soreness, stress-induced tension headaches, joint stiffness during a morning commute, or a child's nocturnal fever. Media buys are designed across broad-reach channels to build and refresh neural memory structures across all category buyers, rather than over-indexing on heavy historical users.
2) Physical availability requires eliminating barriers to purchase across all potential shopping environments. In modern omni-commerce, physical availability integrates traditional shelf placement with digital discoverability: high-visibility placement across retail pharmacy aisles, prime position within rapid-delivery grocery applications, automated subscription programs and prominent rankings within retail search engines.
Commercial Vector | Legacy Pharmaceutical Model | Modern FMCG Consumer Healthcare Model |
Primary Growth Objective | Condition-specific patient adherence and HCP detailing | Household penetration expansion and broad mental availability |
Media Distribution Profile | Linear TV and professional medical print | Connected TV, programmatic video, social creator channels, and retail networks |
Creative Execution | Clinical problem-solution demonstrations and symptom-relief diagrams | Distinctive brand assets, emotional storytelling, and human-centric moments |
Pacing and Flighting | Concentrated seasonal bursts tied to illness waves | Continuous always-on salience paired with programmatic, real-time contextual triggers |
Measurement Strategy | Retrospective panel surveys and regional sales lift modeling | Closed-loop retail media attribution and data clean room analytics |
Digital Reallocation, In Housing and Creative Agility
The transition toward an FMCG operating model has restructured marketing budget allocations across the category. Historically, pharmaceutical consumer divisions directed upwards of 70% of their working media investments into broadcast television and out-of-home advertising.
Today, leading consumer health enterprises have shifted this balance. Opella altered its global expenditure to allocate approximately 60% of all paid media directly into digital channels, reserving only 40% for legacy broadcast channels.
To manage this high-velocity digital media mix, consumer health businesses are moving away from the slow, external-agency models typical of corporate life sciences. Adapting organizational models from FMCG companies like Unilever and P&G, healthcare companies are building internal digital production hubs and media trading desks.
Opella established an 85-person centralised in-house digital studio that brings paid search, programmatic media buying, and retail media operations under direct internal control.
This operational realignment is reinforced by executive hiring trends across the sector. Standalone consumer health companies are recruiting commercial directors, brand strategists, and supply chain leaders from consumer packaged goods leaders such as Reckitt, Procter & Gamble, Nestlé, and
FrieslandCampina.
Reflecting this approach, David Taylor, former Chairman and Chief Executive Officer of Procter & Gamble, was appointed Chairman of Opella’s Supervisory Board following its divestment to CD&R, embedding experienced packaged goods leadership directly into corporate governance.
Dynamic Creative Optimisation and Environmental Contextuality
Because health symptoms occur unpredictably, consumer health marketers are moving away from static, monolithic creative assets. Instead, they are implementing Dynamic Creative Optimisation (DCO) and generative AI production pipelines to personalise advertising messaging at scale.
By connecting creative versioning engines to real-time external data feeds, brands can adjust ad copy, visual assets, and product recommendations to match localised environmental conditions, regional health data, and consumer demographics.
In the allergy treatment segment, Bayer’s Claritin links programmatic display and social video ads to real-time local allergen and pollen count reports, triggering contextual messaging when regional pollen levels cross clinical thresholds. In upper respiratory categories, cough and cold brands adjust digital video creative based on localised temperature drops, changes in barometric pressure, and regional viral prevalence data to show product solutions right as symptoms emerge.
Similarly, Haleon’s digital performance marketing teams partnered with Innovid and The Trade Desk to deploy 343 distinct creative variations for brands such as Panadol and Voltaren in under an hour.
These systems automatically adapt creative hooks based on specific user pain occasions, distinguishing between post-exercise muscle soreness in younger demographics and chronic joint stiffness in older cohorts.
Retail Media Networks and Closed Loop Commerce
The Ascendance of Pharmacy and Omnichannel Retail Networks
The rise of Retail Media Networks (RMNs) represents one of the most significant shifts in consumer health media planning. As retail pharmacy chains and mass retailers, including CVS Health (CVS Media Exchange / CMX), Walgreens Advertising Group (WAG), Walmart Luminate, and Amazon Ads, monetise their point of sale customer data, consumer health brands are reallocating working capital toward these closed ecosystems.
The fundamental advantage of retail media networks over traditional digital channels lies in deterministic, closed-loop attribution. By leveraging identity layers such as the CVS ExtraCare program, which includes more than 90 million active members and accounts for the majority of front-store consumer health sales, brands can link digital ad impressions directly to verified register scans and digital transactions.
This allows media planners to deploy integrated, multi-touch campaigns that combine on site search, off site programmatic display, connected television and digital screens at pharmacy counters.
Category Campaign Focus | Key Performance Multiplier | Primary Attribution Mechanism | Strategic Commerce Impact |
Cough, Cold & Flu Seasonal Care | Up to $22 Return on Ad Spend (ROAS) | Closed-loop ExtraCare POS scan matching | Captures acute symptom surges by connecting environmental triggers to checkout baskets |
OTC Analgesics & Pain Management | 40% larger retail basket sizes | Multi-SKU cross-category purchase reconciliation | High-intent pain purchases serve as anchor transactions that pull broader wellness products into the basket |
Fall / Winter Preventive Restock | Up to 4.76% verified sales lift | Incremental reach modeling and loyalty attribution | Promotes household medicine cabinet preparedness before seasonal peak incidence rates occur |
Audience Optimisation via Predictive AI | +16% expanded incremental audience reach | Machine-learning lookalike modeling on verified shopper baskets | Identifies new consumer health shoppers across adjacent personal care and beauty categories |
Regulatory Boundaries, Medical Review and Privacy Governance
The MLR Review Bottleneck and Modular Content Architecture
While consumer health marketers want to match FMCG speed and flexibility, their campaigns must operate within healthcare regulatory frameworks. The combination of open packaging, automated programmatic bidding, and health oversight introduces compliance requirements that traditional packaged goods brands do not face.
Traditional consumer goods marketing teams can create, approve, and launch social or display creative within hours. In contrast, consumer healthcare content must pass through Medical, Legal, and Regulatory (MLR) review.
Medical reviewers evaluate whether therapeutic claims, symptom durations, and pharmacokinetic comparative statements are supported by clinical trial dossiers or approved product labeling. Legal counsel reviews materials for competitor dispute exposure, copyright compliance, claim substantiation standards, and product liability risk.
Regulatory specialists confirm strict adherence to marketing authorisations, summary of product characteristics (SmPC), and national consumer advertising regulations.
Because traditional MLR reviews took three to six weeks per asset, they created operational bottlenecks that clashed with modern digital performance marketing. Standalone consumer health companies are resolving this friction by adopting modular content models.
By submitting core visual components, headline options, disclaimers, and contextual triggers to MLR review as an interconnected matrix, brands build pre-cleared digital asset management (DAM) libraries.
This allows in-house generative AI and DCO engines to assemble compliant creative variations dynamically, eliminating the need for manual, asset by asset re-reviews.
Statutory Advertising Guardrails in Major Markets
Consumer health brands operating internationally face divergent regulatory frameworks that directly restrict standard FMCG promotional techniques:
In the United Kingdom, consumer medicine advertising is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) alongside self-regulatory enforcement from the Proprietary Association of Great Britain (PAGB).
Under the PAGB Consumer Code and the MHRA Blue Guide, standard FMCG tactics such as product sampling, celebrity endorsements, healthcare professional testimonials, and advertising targeted at children under 16 are prohibited for medicinal products. All consumer advertising produced by PAGB members must undergo formal copy clearance prior to public distribution.
In the United States, direct-to-consumer advertising is permitted under Federal Trade Commission (FTC) and Food and Drug Administration (FDA) guidelines, but brands face strict substantiation standards for comparative claims, required risk and side-effect disclosures, and explicit statutory boundaries between OTC drug monographs and dietary supplements.
Consumer Health Privacy Statutes and Enterprise Clean Rooms
The shift toward programmatic targeting and digital retail media coincides with expanding privacy regulations surrounding health data. Historically, non-prescription brands operated under the assumption that consumer digital browsing fell outside the Health Insurance Portability and Accountability Act (HIPAA), allowing them to deploy standard web tracking pixels, browser cookies, and algorithmic lookalike audiences.
Recent regulatory developments have closed this compliance gap:
The Washington My Health My Data Act (MHMDA), enacted in 2024, established a broad definition of Consumer Health Data (CHD). This definition encompasses any data that identifies a consumer's past, present, or future physical or mental health status, including bodily functions, symptoms, biometric indicators, and algorithmic inferences derived from non-health information like retail searches or browsing habits.
The MHMDA includes a private right of action, requires separate, affirmative opt-in consent for collecting or sharing health-related data, and restricts geofencing around healthcare facilities, limiting conventional behavioural ad targeting across the state.
The FTC Health Breach Notification Rule (HBNR), revised in 2024, confirmed that digital health apps, condition-focused web applications, and wellness trackers violate federal law if they disclose sensitive consumer health information—including mobile device identifiers and browsing histories—to third-party advertising platforms without clear affirmative consent.
To maintain compliant programmatic and retail media operations without exposing the enterprise to regulatory penalties, consumer health businesses are transitioning to Enterprise Data Clean Rooms, such as Snowflake and LiveRamp. Clean rooms allow brands and retailers to link first-party transaction data with addressable media networks via pseudonymised identity identifiers like RampID.
Data clean rooms aggregate information so neither the retailer nor the brand exposes underlying personal health data or individual consumer browsing identities, enabling privacy-safe audience modelling and closed-loop measurement.
Empirical Case Studies of FMCG Media Execution
High Velocity Brand Building and Portfolio Transformation
Opella demonstrates this modern operating model across its portfolio, which includes Allegra, Doliprane, Dulcolax, and Enterogermina. Recognising that consumers frequently research digestive health, allergy relief, and pain management online before purchasing, Opella reorganized its commercial operations.
The company reallocated 60% of its working media budget to digital channels, using internal programmatic execution, search engine optimisation and its 85-person content team to test and deploy creative assets. Over a three-year period, this digital FMCG strategy helped grow e-commerce from 4% to 12% of total business revenue.
Haleon has combined broad-reach brand building with targeted programmatic execution across its pain management portfolio. Facing market saturation for Voltaren among older adults with osteoarthritis, Haleon identified an under-addressed Category Entry Point: adults in their 30s and 40s who experience muscle soreness that disrupts their workout routines.
Haleon deployed dynamic creative optimisation across YouTube and Connected TV, using Innovid engines to serve tailored video assets addressing specific workout recovery challenges. This personalisation approach drove a 94% increase in video click through rates and improved media spend efficiency by 12% compared to historical benchmarks.
At the brand equity level, Haleon launched the "Believe My Pain" campaign under the Advil Pain Equity Project, partnering with the Morehouse School of Medicine and BLKHLTH. Addressing research showing that 74% of Black Americans observe systemic bias in how their physical pain is diagnosed and treated, the initiative combined digital education, healthcare professional roundtables, creator stories, and out-of-home media.
The campaign generated more than 565 million earned impressions and 252 million social impressions, strengthening Advil’s brand equity through cultural relevance and building long-term mental availability.
Reckitt adapted its media approach for Mucinex by shifting away from clinical cough-and-cold television ads toward creator led social platforms. Recognising that younger consumers manage seasonal illness through social channels, Reckitt introduced its "Beat the Zombie Funk" campaign on TikTok, combining interactive creator challenges with direct-to-consumer replenishment funnels.
The initiative generated cultural relevance, received an IN2 SABRE Award, and drove retail and direct-to-consumer sales.
Bayer connected corporate brand purpose with programmatic ad execution through the Claritin "DiversiTree Project". Working with the Asthma and Allergy Foundation of America (AAFA), Claritin highlighted botanical disparities in urban landscaping, specifically the over planting of male trees, which raises airborne pollen levels.
Bayer paired this public health educational initiative with programmatic display and search campaigns triggered by live pollen forecasting data, driving retail conversion when localised allergen counts spiked.
Strategic Dilemmas and Emerging Media Horizons
Internal Capital Friction and the Performance Marketing Trap
Adopting an FMCG media model introduces structural organizational friction within consumer health businesses. The primary issue centers on internal retail media budget ownership. Historically, pharmaceutical marketing separated its capital allocations into distinct corporate silos: brand marketing managed linear direct to consumer broadcast budgets, shopper marketing oversaw physical store promotions, and e-commerce teams controlled digital marketplace spend.
Because modern Retail Media Networks span the entire marketing funnel, offering Connected TV for brand awareness, off-site social display for consideration, and on-site search for point-of-sale conversion, internal departments frequently compete over budget control.
Sales teams and retail account managers often view RMN investment as a mandatory commercial trade concession required to secure physical shelf space. Conversely, global brand directors often view retail media as an expensive short-term performance cost that diverts working capital from long-term brand-building campaigns.
Resolving this tension requires consumer health enterprises to establish unified commercial growth teams that measure media investments holistically using marketing mix modelling (MMM) and matched-market geo-testing rather than siloed channel metrics.
A related strategic vulnerability is over-indexing on short-term performance marketing. Because retail media, paid search, and conversion-focused social ads provide immediate ROAS metrics, corporate management can be tempted to over-allocate capital to lower-funnel channels at the expense of long-term brand building.
However, consumer purchase cycles in over the counter healthcare are episodic; shoppers buy specialised cough medicines, pain relievers, or allergy therapies only a few times per year.
If a consumer health enterprise allocates its marketing budget entirely to capturing immediate, bottom-of-funnel demand, it fails to build persistent mental availability among future category buyers. When a sudden health need arises, an unexposed consumer will select whatever brand comes to mind first or default to lower-priced private-label alternatives on the shelf.
High-performing consumer healthcare businesses address this risk by maintaining a balanced budget allocation, typically reserving roughly 60% of media investments for broad-reach, emotional brand building to anchor Category Entry Points, while deploying the remaining 40% into programmatic performance channels and retail search conversion.
Generative Engine Optimisation and Owned Health Ecosystems
The intersection of consumer health and FMCG media continues to adapt alongside developments in search behaviour and consumer technology:
Consumers are increasingly turning to generative AI platforms such as ChatGPT, Claude, and Gemini as initial symptom-checking and health research tools. Because these large language models return conversational summaries rather than standard paid search engine results pages, brands must monitor their visibility within AI answers.
Consumer health marketers are investing in Generative Engine Optimisation (GEO), publishing structured, medically validated content to ensure their products are cited as recommended treatments when users query symptoms online.
Furthermore, as data privacy legislation restricts third-party behavioral tracking, consumer health brands are investing in owned digital platforms. Examples include Kenvue’s Imodium "Gut2Know" digestive tracking application and Haleon’s interactive Centrum wellness assessments.
These digital services offer value to consumers while generating first-party, opt-in zero-party data. By collecting health information through transparent customer interactions, brands can personalise consumer communication compliantly, without running afoul of emerging health-data privacy laws.
Synthesis and Strategic Outlook
The migration of consumer healthcare toward FMCG media strategies marks a permanent operational shift in how over-the-counter medicines and wellness products are marketed and sold.
Freed from pharmaceutical clinical timelines, standalone pure-play leaders, including Haleon, Kenvue and Opella are demonstrating that sustained commercial growth requires combining clinical evidence with consumer marketing principles.
By adopting the principles of physical and mental availability, establishing internal creative studios, leveraging retail media networks, and developing modular compliance workflows, these organisations are establishing a distinct operating model for consumer healthcare.
Long-term category leadership requires integrating these capabilities. Brands that rely exclusively on functional medical claims risk losing market share to agile challengers and private label alternatives.
Conversely, brands that adopt consumer goods tactics without respecting health data privacy laws or maintaining scientific claim substantiation face regulatory enforcement and brand erosion.
The sustainable model for everyday consumer healthcare balances scientific credibility with high-velocity marketing execution, ensuring brands remain both trusted by healthcare professionals and top of mind for consumers when health needs arise.
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Healthcare.Digital serves as a research platform for Nelson Advisors’ perspectives on deals, valuations and structural shifts reshaping Global Digital Health, MedTech, Healthcare AI and Health IT. https://www.healthcare.digital
Nelson Advisors is one of Europe's leading mergers and acquisitions advisory firms, exclusively dedicated to the dynamic and rapidly evolving healthcare technology sector. With a deep understanding of market dynamics and technological advancements, they empower innovative HealthTech companies and strategic investors to navigate complex transactions and achieve their growth ambitions. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #Genomics
Nelson Advisors
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments